Calling all Bioanalysts: We’re Making Bioanalytical Selectivity Challenges History

Apr 17, 2018 | Biopharma, Blogs, Pharma | 0 comments

High selectivity is a key component of successful quantitative bioanalysis. As a bioanalyst, we need consistently accurate and robust quantitation of small molecule therapeutics and metabolites. Challenged by complicated matrix interferences, high baseline signal, and lack of isomer resolution, we need to embrace innovative strategies to increase the sensitivity and selectivity of our assays. If our ‘go-to’ is the development of complex HPLC conditions or modifying sample preparation procedures, we will find ourselves bogged down with time-consuming methods that reduce sample throughput. So, what’s the answer?

Imagine a new dimension in bioanalytical selectivity that you never thought possible. One that enables robust and reproducible bioanalytical methods, and meets high throughput requirements. One that reduces background noise, eliminates interferences and separates highly similar compounds, without having to resort to complex HPLC conditions or sample workup procedures.

Well this could very much be your reality.

Significant advances have been made in increasing MS/MS selectivity beyond the gold standard MRM. For example, MRM3 on the QTRAP® systems adds additional selectivity by increasing the number of fragmentation steps by the mass analyzer. Ion mobility presents another attractive option by introducing an orthogonal level of separation after sample ionization, followed by traditional m/z detection.

Although ion mobility techniques have been used extensively for qualitative applications, they have traditionally lacked the required ruggedness and speed required for quantitative bioanalysis. Not anymore, and hereby the end of the history lesson!

SelexION® DMS Technology provides an orthogonal level of separation. It is the first differential ion mobility separation technology to combine sensitivity and selectivity with unmatched reproducibility and robustness. It delivers enhanced analytical separations on demand for isobaric species and co-eluting contaminants, all in an elegantly simple package.

Along with the QTRAP 6500+ or 5500 systems, you get the power of differential ion mobility separation, enabled by multiple new innovations in ion mobility:

  • The introduction of chemical modifier adds a new dimension to selectivity and dramatically increases separation capacity.
  • Planar geometry results in high speed and minimal diffusion losses for maximum sensitivity and UHPLC compatibility.
  • Highly robust, reproducible, and stable for use in regulated bioanalysis.
  • Easy to maintain, and can be Installed or removed in minutes with no need to break vacuum on the mass spectrometer, or use any tools.

Do you want to know more? We thought you might, so we have developed some tech notes to support you in your quest to achieve high performing small molecule therapeutics and metabolite quantitation workflows in drug discovery and development:

  • SelexION Technology: A New Solution to Selectivity Challenges in Quantitative Bioanalysis
  • Separation of Diastereomeric Flubatine Metabolites using SelexION Technology
  • Improving Multiple Reaction Monitoring (MRM) Selectivity for Mesalamine with the SelexION differential mobility separation device

If you are challenged by complex small molecule therapeutics and metabolite quantitation requiring advanced analytical selectivity, look no further. Download the eBook and get access to these technical papers, and so much more. Find out about The Science Behind SelexION Differential Ion Mobility Technology and how SeleXION Addresses Your Biggest Analytical Challenges.Download the eBook >

Understanding PFAS and its impact on U.S. drinking water

In recent years, per- and polyfluoroalkyl substances (PFAS), often referred to as “forever chemicals,” have become a growing topic of interest due to their persistence in the environment and potential health risks. These synthetic compounds have been widely used in various industrial applications and consumer products since the 1940s. PFAS can be found in the air, soil, and water, and studies have shown that most people have detectable levels of PFAS in their bloodstream. One of the main exposure pathways for humans is through drinking water, particularly in communities located near industrial sites, military bases, or areas where firefighting foam has been used.

Selecting an LC-MS system for quantitation of pharmaceutical drug development

We understand you are busy, needing to prioritize running instruments, reporting results and managing your laboratory to meet deadlines. We created a solution guide to explain how SCIEX systems fit in the drug development pipeline to save you time evaluating options.

Nitrosamines: Where are we now?

Nitrosamines are a large group of N-nitroso compounds that share a common functional N-N=O group. They are produced by a chemical reaction between a nitrosating agent and a secondary or tertiary amine. Back in 2018, nitrosamines suddenly found themselves in the spotlight when they were unexpectedly detected in medications for high blood pressure. Since then, they have been found in several other prescription medications, including those for heartburn, acid reflux and diabetes, resulting in manufacturers recalling some common medications.

Posted by

0 Comments

Submit a Comment

Wordpress Social Share Plugin powered by Ultimatelysocial